Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis

Trial Profile

Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2015

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Acorda Therapeutics
  • Most Recent Events

    • 09 Nov 2015 Post-hoc subgroup analysis results published in the Clinical Therapeutics
    • 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 13 Mar 2013 Subgroup analysis presented at the the 65th American Academy of Neurology Annual Meeting (AAN-2013), according to an Acorda Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top